Bright days ahead for Optimum and its clients

Summer is just around the corner and there was real optimism in the air this week as Optimum’s clients looked forward to 2024, with the conference season about to start. 

Medicxi Announces £40m investment in D3 Bio 

Medicxi, a leading European life sciences investment firm, on Monday announced an investment of $40 million in D3 Bio, a biotechnology company based in Shanghai, China. D3 Bio is focused on the discovery, development, and registration of innovative medicines in oncology and immunology. 

The investment will accelerate the development of D3 Bio’s innovative pipeline of oncology compounds, including D3S-001 a potentially best-in-class KRAS G12C inhibitor. Francesco De Rubertis, Partner at Medicxi, will join the Board of D3 Bio. 

Calliditas announces data presentations at ISN World Congress of Nephrology 

Calliditas Therapeutics AB on Monday announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology’s World Congress of Nephrology.  The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024. 

Investigators will deliver additional analyses from the 2-year Phase 3 NeflgArd trial with Nefecon Tarpeyo/ Kinpeygo (budesonide) delayed release capsules in patients with IgA nephropathy (IgAN). Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial. There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.  

Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease 

Vivet Therapeutics, a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces that it has dosed its first patient with its lead program VTX-801 in Cohort 2 of its ongoing GATEWAY Clinical Trial for the treatment of Wilson Disease (WD). Initiation of Cohort 2 followed the successful completion of Cohort 1 and approval from an independent Data Monitoring Committee (DMC) to proceed. 

4SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas 

4SC AG, a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma CTCL, on Thursday announced that renowned dermato-oncology expert and principal investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, will present data from the pivotal RESMAIN study of resminostat (Kinselby) at the 5th World Congress of Cutaneous Lymphomas (5WCCL), at the City of Hope, Pasadena, California, USA, April 11-13, 2024. 

Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice. 

SpliceBio to Attend Key Scientific and Investor Conferences in April to June 2024 

Don’t miss out on your chance to meet with our client SpliceBio, a genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, at conferences on both sides of the Atlantic! 

Starting with the Cell & Gene Meeting on the Med in Rome, Italy this week, the Anglonordic Life Science Conference in London next week and including the Association for Research in Vision and Ophthalmology (ARVO) in early May, the SpliceBio team will be on hand to discuss the firm’s lead therapy targeting Stargadt disease. 

Meet the Optimum team at the Anglonordic Life Science Conference 

Optimum Strategic Communications is once again proud to be Event Programmer at this year’s Anglonordic Life Science Conference in London. 

The conference is a unique opportunity to discover the latest trends and technology in life sciences,  allowing a range of stakeholders to network, collaborate and ultimately transform healthcare for patients. 

This year’s 20th anniversary event kicks off with a reception on Wednesday 17 April at the London Institute for Healthcare Engineering at King’s College, London, situated on the banks of the Thames and embedded in the St Thomas’ Hospital Campus. 

The main event on Thursday 18 April, on the 3rd floor of The County Hall, London with a packed programme beginning with registration at 8am and concluding with an afternoon drinks reception at 5.30pm. 

Speakers include representatives of Optimum’s clients and the Optimum team led by CEO Mary Clark will be attending – we would love to meet you there at the networking events!